;PMID: 9107428
;source_file_1308.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..54] = [t:0..54]
;1)sentence:[e:59..108] = [t:59..108]
;2)section:[e:112..207] = [t:112..207]
;3)section:[e:211..307] = [t:211..307]
;4)sentence:[e:311..552] = [t:311..552]
;5)sentence:[e:554..673] = [t:554..673]
;6)sentence:[e:674..916] = [t:674..916]
;7)sentence:[e:917..1039] = [t:917..1039]
;8)sentence:[e:1040..1230] = [t:1040..1230]
;9)sentence:[e:1231..1386] = [t:1231..1386]
;10)sentence:[e:1387..1555] = [t:1387..1555]
;11)sentence:[e:1557..1629] = [t:1557..1629]
;12)sentence:[e:1630..1738] = [t:1630..1738]
;13)sentence:[e:1739..1887] = [t:1739..1887]
;14)section:[e:1891..1935] = [t:1891..1935]

;section 0 Span:0..54
;Cancer Epidemiol Biomarkers Prev  1997 Apr;6(4):239-43
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..16] Epidemiol) (NNP:[17..27] Biomarkers)
        (NNP:[28..32] Prev) (CD:[34..38] 1997) (CC:[39..43] Apr;)
        (CD:[43..44] 6) (NN:[44..45] -LRB-) (NN:[45..46] 4) (NN:[46..47] -RRB-)
        (::[47..48] :) (CD:[48..51] 239) (CD:[51..54] -43)))

;sentence 1 Span:59..108
;Ras oncogene mutations in childhood brain tumors.
;[59..62]:gene-rna:"Ras"
;[85..94]:malignancy-developmental-state:"childhood"
;[95..107]:malignancy-type:"brain tumors"
(SENT
  (NP-HLN
    (NP (NN:[59..62] Ras) (NN:[63..71] oncogene) (NNS:[72..81] mutations))
    (PP-LOC (IN:[82..84] in)
      (NP (NN:[85..94] childhood)
         (NN:[95..100] brain) (NNS:[101..107] tumors)))
    (.:[107..108] .)))

;section 2 Span:112..207
;Maltzman TH, Mueller BA, Schroeder J, Rutledge JC, Patterson K,
;Preston-Martin  S, Faustman EM.
(SEC
  (FRAG (NNP:[112..120] Maltzman) (NNP:[121..123] TH) (,:[123..124] ,)
        (NNP:[125..132] Mueller) (NNP:[133..135] BA) (,:[135..136] ,)
        (NNP:[137..146] Schroeder) (NNP:[147..149] J,) (NNP:[150..158] Rutledge)
        (NNP:[159..161] JC) (,:[161..162] ,) (NNP:[163..172] Patterson)
        (NNP:[173..175] K,) (NNP:[176..183] Preston) (NNP:[183..190] -Martin)
        (NNP:[192..193] S) (,:[193..194] ,) (NNP:[195..203] Faustman)
        (NN:[204..206] EM) (.:[206..207] .)))

;section 3 Span:211..307
;Division of Gastroenterology, University of Colorado Health Sciences Center, 
;Denver 80262, USA.
(SEC
  (FRAG (NNP:[211..219] Division) (IN:[220..222] of)
        (NNP:[223..239] Gastroenterology) (,:[239..240] ,)
        (NNP:[241..251] University) (IN:[252..254] of) (NNP:[255..263] Colorado)
        (NNP:[264..270] Health) (NNP:[271..279] Sciences)
        (NNP:[280..286] Center) (,:[286..287] ,) (NNP:[289..295] Denver)
        (CD:[296..301] 80262) (,:[301..302] ,) (NNP:[303..306] USA)
        (.:[306..307] .)))

;sentence 4 Span:311..552
;Although N-nitroso compounds (NNC) are ubiquitous in the human environment
;and  are known neurocarcinogens in animal models, results of epidemiological
;studies  have not yet convincingly associated NNCs with brain tumor
;occurrence in humans.
;[519..530]:malignancy-type:"brain tumor"
(SENT
  (S
    (SBAR-ADV (IN:[311..319] Although)
      (S
        (NP-SBJ
          (NP (NN:[320..329] N-nitroso) (NNS:[330..339] compounds))
          (NP (-LRB-:[340..341] -LRB-) (NN:[341..344] NNC)
              (-RRB-:[344..345] -RRB-)))
        (VP
          (VP (VBP:[346..349] are)
            (ADJP-PRD (JJ:[350..360] ubiquitous))
            (PP-LOC (IN:[361..363] in)
              (NP (DT:[364..367] the) (JJ:[368..373] human)
                  (NN:[374..385] environment))))
          (CC:[386..389] and)
          (VP (VBP:[391..394] are)
            (NP-LOC (VBN:[395..400] known) (NNS:[401..417] neurocarcinogens))
            (PP (IN:[418..420] in)
              (NP (NN:[421..427] animal) (NNS:[428..434] models)))))))
    (,:[434..435] ,)
    (NP-SBJ
      (NP (NNS:[436..443] results))
      (PP (IN:[444..446] of)
        (NP (JJ:[447..462] epidemiological) (NNS:[463..470] studies))))
    (VP (VBP:[472..476] have) (RB:[477..480] not)
      (ADVP-TMP (RB:[481..484] yet))
      (ADVP (RB:[485..497] convincingly))
      (VP (VBN:[498..508] associated)
        (NP (NNS:[509..513] NNCs))
        (PP-CLR (IN:[514..518] with)
          (NP
            (NP
               (NN:[519..524] brain) (NN:[525..530] tumor)
              (NN:[531..541] occurrence))
            (PP (IN:[542..544] in)
              (NP (NNS:[545..551] humans)))))))
    (.:[551..552] .)))

;sentence 5 Span:554..673
;Animal studies have suggested that specific codons (12, 13, and 61) in the
;ras  family are mutable by exposure to NNCs.
;[598..604]...[618..620]:variation-location:"codons"..."61"
;[598..604]...[610..612]:variation-location:"codons"..."13"
;[598..604]...[606..608]:variation-location:"codons"..."12"
;[629..632]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ (NN:[554..560] Animal) (NNS:[561..568] studies))
    (VP (VBP:[569..573] have)
      (VP (VBN:[574..583] suggested)
        (SBAR (IN:[584..588] that)
          (S
            (NP-SBJ
              (NP (JJ:[589..597] specific) (NNS:[598..604] codons)
                (PRN (-LRB-:[605..606] -LRB-)
                  (NP
                    (NP (CD:[606..608] 12))
                    (,:[608..609] ,)
                    (NP (CD:[610..612] 13))
                    (,:[612..613] ,) (CC:[614..617] and)
                    (NP (CD:[618..620] 61)))
                  (-RRB-:[620..621] -RRB-)))
              (PP (IN:[622..624] in)
                (NP (DT:[625..628] the) (NN:[629..632] ras)
                    (NN:[634..640] family))))
            (VP (VBP:[641..644] are)
              (ADJP-PRD (JJ:[645..652] mutable)
                (PP (IN:[653..655] by)
                  (NP
                    (NP (NN:[656..664] exposure))
                    (PP (TO:[665..667] to)
                      (NP (NNS:[668..672] NNCs)))))))))))
    (.:[672..673] .)))

;sentence 6 Span:674..916
;The purpose of this study was to measure  the presence of mutations in the
;ras family of oncogenes in tissue from  childhood brain (CB) tumors as a
;preliminary step toward investigating their  potential use as biomarkers of
;chemical exposure.
;[749..752]:gene-rna:"ras"
;[789..798]:malignancy-developmental-state:"childhood"
;[799..816]:malignancy-type:"brain (CB) tumors"
;[806..808]:malignancy-type:"CB"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[674..677] The) (NN:[678..685] purpose))
      (PP (IN:[686..688] of)
        (NP (DT:[689..693] this) (NN:[694..699] study))))
    (VP (VBD:[700..703] was)
      (S-PRD
        (NP-SBJ (-NONE-:[703..703] *))
        (VP (TO:[704..706] to)
          (VP (VB:[707..714] measure)
            (NP
              (NP (DT:[716..719] the) (NN:[720..728] presence))
              (PP (IN:[729..731] of)
                (NP
                  (NP (NNS:[732..741] mutations))
                  (PP (IN:[742..744] in)
                    (NP
                      (NP (DT:[745..748] the) (NN:[749..752] ras)
                          (NN:[753..759] family))
                      (PP (IN:[760..762] of)
                        (NP (NNS:[763..772] oncogenes))))))))
            (PP-LOC (IN:[773..775] in)
              (NP
                (NP (NN:[776..782] tissue))
                (PP (IN:[783..787] from)
                  (NP
                    (NML
                      (NML (NN:[789..798] childhood) (NN:[799..804] brain))
                      (NML (-LRB-:[805..806] -LRB-) (NN:[806..808] CB)
                           (-RRB-:[808..809] -RRB-)))
                    (NNS:[810..816] tumors)))))
            (PP (IN:[817..819] as)
              (NP
                (NP (DT:[820..821] a) (JJ:[822..833] preliminary)
                    (NN:[834..838] step))
                (PP (IN:[839..845] toward)
                  (S-NOM
                    (NP-SBJ (-NONE-:[845..845] *))
                    (VP (VBG:[846..859] investigating)
                      (NP
                        (NP (PRP$:[860..865] their) (JJ:[867..876] potential)
                            (NN:[877..880] use))
                        (PP (IN:[881..883] as)
                          (NP
                            (NP (NNS:[884..894] biomarkers))
                            (PP (IN:[895..897] of)
                              (NP (JJ:[898..906] chemical)
                                  (NN:[907..915] exposure)))))))))))))))
    (.:[915..916] .)))

;sentence 7 Span:917..1039
;DNA was extracted from  paraffin-embedded formalin-fixed CB tumors from
;tissues resected during  neurosurgical operations.
;[974..983]:malignancy-type:"CB tumors"
(SENT
  (S
    (NP-SBJ-1 (NN:[917..920] DNA))
    (VP (VBD:[921..924] was)
      (VP (VBN:[925..934] extracted)
        (NP-1 (-NONE-:[934..934] *))
        (PP-CLR (IN:[935..939] from)
          (NP
            (NP
              (ADJP (NN:[941..949] paraffin) (HYPH:[949..950] -)
                    (VBN:[950..958] embedded))
              (ADJP (NN:[959..967] formalin) (HYPH:[967..968] -)
                    (VBN:[968..973] fixed))
               (NN:[974..976] CB) (NNS:[977..983] tumors))
            (PP (IN:[984..988] from)
              (NP
                (NP (NNS:[989..996] tissues))
                (VP (VBN:[997..1005] resected)
                  (NP (-NONE-:[1005..1005] *))
                  (PP-TMP (IN:[1006..1012] during)
                    (NP (JJ:[1014..1027] neurosurgical)
                        (NNS:[1028..1038] operations))))))))))
    (.:[1038..1039] .)))

;sentence 8 Span:1040..1230
;Using the PCR, designed RFLP-screening methods, and  sequencing, we attempted
;to screen brain tumors from 46 children for the  presence of H, K, and N-ras
;mutations at codons 12, 13, and 61.
;[1128..1140]:malignancy-type:"brain tumors"
;[1149..1157]:malignancy-developmental-state:"children"
;[1179..1180]...[1191..1194]:gene-rna:"H"..."ras"
;[1182..1183]...[1191..1194]:gene-rna:"K"..."ras"
;[1189..1194]:gene-rna:"N-ras"
;[1195..1204]:variation-event:"mutations"
;[1208..1217]:variation-location:"codons 12"
;[1208..1214]...[1227..1229]:variation-location:"codons"..."61"
;[1208..1214]...[1219..1221]:variation-location:"codons"..."13"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[1040..1040] *))
      (VP (VBG:[1040..1045] Using)
        (NP
          (NP (DT:[1046..1049] the) (NN:[1050..1053] PCR))
          (,:[1053..1054] ,)
          (NP (VBN:[1055..1063] designed)
            (ADJP (NN:[1064..1068] RFLP) (HYPH:[1068..1069] -)
                  (VBG:[1069..1078] screening))
            (NNS:[1079..1086] methods))
          (,:[1086..1087] ,) (CC:[1088..1091] and)
          (NP (NN:[1093..1103] sequencing)))))
    (,:[1103..1104] ,)
    (NP-SBJ (PRP:[1105..1107] we))
    (VP (VBD:[1108..1117] attempted)
      (S
        (NP-SBJ (-NONE-:[1117..1117] *))
        (VP (TO:[1118..1120] to)
          (VP (VB:[1121..1127] screen)
            (NP
              (NP (NN:[1128..1133] brain) (NNS:[1134..1140] tumors))
              (PP (IN:[1141..1145] from)
                (NP (CD:[1146..1148] 46) (NNS:[1149..1157] children))))
            (PP (IN:[1158..1161] for)
              (NP
                (NP (DT:[1162..1165] the) (NN:[1167..1175] presence))
                (PP (IN:[1176..1178] of)
                  (NP
                    (NP
                      (NP
                        (NML (NN:[1179..1180] H)
                          (NML-2 (-NONE-:[1180..1180] *P*)))
                        (NML-1 (-NONE-:[1180..1180] *P*)))
                      (,:[1180..1181] ,)
                      (NP
                        (NML (NN:[1182..1183] K)
                          (NML-2 (-NONE-:[1183..1183] *P*)))
                        (NML-1 (-NONE-:[1183..1183] *P*)))
                      (,:[1183..1184] ,) (CC:[1185..1188] and)
                      (NP
                        (NML (NN:[1189..1190] N) (HYPH:[1190..1191] -)
                          (NML-2 (NN:[1191..1194] ras)))
                        (NML-1 (NNS:[1195..1204] mutations))))
                    (PP-LOC (IN:[1205..1207] at)
                      (NP
                        (NP
                          (NML-3 (NNS:[1208..1214] codons))
                          (CD:[1215..1217] 12))
                        (,:[1217..1218] ,)
                        (NP
                          (NML-3 (-NONE-:[1218..1218] *P*))
                          (CD:[1219..1221] 13))
                        (,:[1221..1222] ,) (CC:[1223..1226] and)
                        (NP
                          (NML-3 (-NONE-:[1226..1226] *P*))
                          (CD:[1227..1229] 61))))))))))))
    (.:[1229..1230] .)))

;sentence 9 Span:1231..1386
;Screening for  oncogene mutations using PCR, RFLP methods, and DNA sequencing
;was successfully  completed for a high proportion of the available
;specimens.
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1231..1240] Screening))
      (PP (IN:[1241..1244] for)
        (NP
          (NP (NN:[1246..1254] oncogene) (NNS:[1255..1264] mutations))
          (VP (VBG:[1265..1270] using)
            (NP
              (NP (NN:[1271..1274] PCR))
              (,:[1274..1275] ,)
              (NP (NN:[1276..1280] RFLP)
                (NML (NNS:[1281..1288] methods)))
              (,:[1288..1289] ,) (CC:[1290..1293] and)
              (NP (NN:[1294..1297] DNA) (NN:[1298..1308] sequencing)))))))
    (VP (VBD:[1309..1312] was)
      (ADVP (RB:[1313..1325] successfully))
      (VP (VBN:[1327..1336] completed)
        (NP-1 (-NONE-:[1336..1336] *))
        (PP (IN:[1337..1340] for)
          (NP
            (NP (DT:[1341..1342] a) (JJ:[1343..1347] high)
                (NN:[1348..1358] proportion))
            (PP (IN:[1359..1361] of)
              (NP (DT:[1362..1365] the) (JJ:[1366..1375] available)
                  (NNS:[1376..1385] specimens)))))))
    (.:[1385..1386] .)))

;sentence 10 Span:1387..1555
;Astrocytoma  specimens from three children for whom screening with PCR was
;successfully  completed were found to contain CAA-->GAA point mutations in
;K-ras at codon 61.
;[1387..1398]:malignancy-type:"Astrocytoma"
;[1421..1429]:malignancy-developmental-state:"children"
;[1508..1511]:variation-state-original:"CAA"
;[1514..1517]:variation-state-altered:"GAA"
;[1518..1533]:variation-type:"point mutations"
;[1537..1542]:gene-rna:"K-ras"
;[1546..1554]:variation-location:"codon 61"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1387..1398] Astrocytoma) (NNS:[1400..1409] specimens))
      (PP (IN:[1410..1414] from)
        (NP
          (NP (CD:[1415..1420] three) (NNS:[1421..1429] children))
          (SBAR
            (WHPP-1 (IN:[1430..1433] for)
              (WHNP (WP:[1434..1438] whom)))
            (S
              (NP-SBJ
                (NP (NN:[1439..1448] screening))
                (PP (IN:[1449..1453] with)
                  (NP (NN:[1454..1457] PCR))))
              (VP (VBD:[1458..1461] was)
                (ADVP (RB:[1462..1474] successfully))
                (VP (VBN:[1476..1485] completed)
                  (PP-1 (-NONE-:[1485..1485] *T*)))))))))
    (VP (VBD:[1486..1490] were)
      (VP (VBN:[1491..1496] found)
        (S
          (NP-SBJ-2 (-NONE-:[1496..1496] *))
          (VP (TO:[1497..1499] to)
            (VP (VB:[1500..1507] contain)
              (NP
                (NP
                  (NML
                    (NML (NN:[1508..1511] CAA))
                    (PP (SYM:[1511..1514] -->)
                      (NP (NN:[1514..1517] GAA))))
                   (NN:[1518..1523] point) (NNS:[1524..1533] mutations))
                (PP (IN:[1534..1536] in)
                  (NP (NN:[1537..1542] K-ras))))
              (PP-LOC (IN:[1543..1545] at)
                (NP (NN:[1546..1551] codon) (CD:[1552..1554] 61))))))))
    (.:[1554..1555] .)))

;sentence 11 Span:1557..1629
;None of the specimens contained mutations at any of the other locations.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1557..1561] None))
      (PP (IN:[1562..1564] of)
        (NP (DT:[1565..1568] the) (NNS:[1569..1578] specimens))))
    (VP (VBD:[1579..1588] contained)
      (NP (NNS:[1589..1598] mutations))
      (PP-LOC (IN:[1599..1601] at)
        (NP
          (NP (DT:[1602..1605] any))
          (PP (IN:[1606..1608] of)
            (NP (DT:[1609..1612] the) (JJ:[1613..1618] other)
                (NNS:[1619..1628] locations))))))
    (.:[1628..1629] .)))

;sentence 12 Span:1630..1738
;These  results, although preliminary, provide a potential clue for future
;mechanistic  studies of CB tumors.
;[1728..1737]:malignancy-type:"CB tumors"
(SENT
  (S
    (NP-SBJ (DT:[1630..1635] These) (NNS:[1637..1644] results))
    (,:[1644..1645] ,)
    (PP (IN:[1646..1654] although)
      (NP (JJ:[1655..1666] preliminary)))
    (,:[1666..1667] ,)
    (VP (VBP:[1668..1675] provide)
      (NP (DT:[1676..1677] a) (JJ:[1678..1687] potential) (NN:[1688..1692] clue))
      (PP (IN:[1693..1696] for)
        (NP
          (NP (JJ:[1697..1703] future) (JJ:[1704..1715] mechanistic)
              (NNS:[1717..1724] studies))
          (PP (IN:[1725..1727] of)
            (NP (NN:[1728..1730] CB) (NNS:[1731..1737] tumors))))))
    (.:[1737..1738] .)))

;sentence 13 Span:1739..1887
;The possible roles of NNCs in inducing this mutation, or  of this mutation as
;an early or late event in tumor progression, however, remain  unclear.
;[1778..1791]:variation-event:"this mutation"
;[1800..1813]:variation-event:"this mutation"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1739..1742] The) (JJ:[1743..1751] possible)
          (NNS:[1752..1757] roles))
      (PP
        (PP (IN:[1758..1760] of)
          (NP
            (NP (NNS:[1761..1765] NNCs))
            (PP (IN:[1766..1768] in)
              (S-NOM
                (NP-SBJ (-NONE-:[1768..1768] *))
                (VP (VBG:[1769..1777] inducing)
                  (NP (DT:[1778..1782] this) (NN:[1783..1791] mutation)))))))
        (,:[1791..1792] ,) (CC:[1793..1795] or)
        (PP (IN:[1797..1799] of)
          (NP
            (NP (DT:[1800..1804] this) (NN:[1805..1813] mutation))
            (PP (IN:[1814..1816] as)
              (NP
                (NP (DT:[1817..1819] an)
                  (NML
                    (NML (JJ:[1820..1825] early)
                      (NML-1 (-NONE-:[1825..1825] *P*)))
                    (CC:[1826..1828] or)
                    (NML (JJ:[1829..1833] late)
                      (NML-1 (NN:[1834..1839] event)))))
                (PP (IN:[1840..1842] in)
                  (NP (NN:[1843..1848] tumor) (NN:[1849..1860] progression)))))))))
    (,:[1860..1861] ,)
    (ADVP (RB:[1862..1869] however))
    (,:[1869..1870] ,)
    (VP (VBP:[1871..1877] remain)
      (ADJP-PRD (JJ:[1879..1886] unclear)))
    (.:[1886..1887] .)))

;section 14 Span:1891..1935
;PMID: 9107428 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1891..1895] PMID) (::[1895..1896] :) (CD:[1897..1904] 9107428)
        (NN:[1905..1906] -LSB-) (NNP:[1906..1912] PubMed) (::[1913..1914] -)
        (NN:[1915..1922] indexed) (IN:[1923..1926] for)
        (NNP:[1927..1935] MEDLINE-RSB-)))
